1.71
price down icon1.72%   -0.03
after-market 시간 외 거래: 1.63 -0.08 -4.68%
loading
전일 마감가:
$1.74
열려 있는:
$1.74
하루 거래량:
59,228
Relative Volume:
0.01
시가총액:
$10.50M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.2785
EPS:
-6.14
순현금흐름:
$-155.03M
1주 성능:
-10.94%
1개월 성능:
-26.61%
6개월 성능:
+211.36%
1년 성능:
-37.82%
1일 변동 폭
Value
$1.62
$1.74
1주일 범위
Value
$1.62
$2.05
52주 변동 폭
Value
$0.16
$6.83

바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile

Name
명칭
Bioxcel Therapeutics Inc
Name
전화
203-643-8060
Name
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
직원
37
Name
트위터
@bioxcel_tx
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
BTAI's Discussions on Twitter

BTAI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BTAI
Bioxcel Therapeutics Inc
1.71 10.50M 1.38M -179.05M -155.03M -6.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-02-21 다운그레이드 UBS Buy → Neutral
2023-08-15 다운그레이드 Mizuho Buy → Neutral
2023-07-17 다운그레이드 Guggenheim Buy → Neutral
2023-03-10 다운그레이드 Jefferies Buy → Hold
2022-12-01 업그레이드 Goldman Sell → Neutral
2022-07-07 개시 Mizuho Buy
2022-04-06 재확인 BofA Securities Buy
2021-11-15 다운그레이드 Goldman Neutral → Sell
2021-04-09 개시 Berenberg Buy
2021-02-01 개시 UBS Buy
2020-10-30 개시 Goldman Buy
2020-09-02 개시 Jefferies Buy
2020-08-17 재확인 H.C. Wainwright Buy
2020-07-08 재확인 H.C. Wainwright Buy
2020-06-04 개시 Guggenheim Buy
2020-04-01 개시 BofA/Merrill Buy
2020-02-26 재확인 H.C. Wainwright Buy
2020-01-08 재확인 H.C. Wainwright Buy
2019-11-12 개시 SunTrust Buy
모두보기

바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스

pulisher
Apr 06, 2025

BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Apr 06, 2025
pulisher
Apr 05, 2025

BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

BioXcel Therapeutics stock hits 52-week low at $1.72 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia

Apr 04, 2025
pulisher
Apr 03, 2025

BioXcel Therapeutics Initiates At-The-Market Equity Program By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener

Apr 03, 2025
pulisher
Apr 02, 2025

ROSEN, A RANKED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI - AsiaOne

Apr 02, 2025
pulisher
Mar 29, 2025

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 27, 2025

BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 26, 2025
pulisher
Mar 22, 2025

BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com India

Mar 22, 2025
pulisher
Mar 22, 2025

BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India

Mar 21, 2025
pulisher
Mar 19, 2025

Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq

Mar 19, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - MarketScreener

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 10, 2025
pulisher
Mar 09, 2025

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey

Mar 09, 2025
pulisher
Mar 08, 2025

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan

Mar 07, 2025

바이오엑셀 테라퓨틱스 (BTAI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
자본화:     |  볼륨(24시간):